IL6 and non-Hodgkin lymphoma: The recent demonstration that TME-produced IL-6 is critical for PCT in mice (Rosean et al., 2015) may also be relevant for myeloma because it suggest that human IL-6 promoter polymorphisms associated with predisposition to non-Hodgkin’s lymphoma and Hodgkin’s lymphoma (Peng et al., 2018) are in fact TME risk modifiers of neoplastic B cell and plasma cell development.